搜尋結果
Cytochrome P450 1A2 (abbreviated CYP1A2), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the human body. In humans, the CYP1A2 enzyme is encoded by the CYP1A2 gene.
- CYP1A2, CP12, P3-450, P450(PA), cytochrome P450 family 1 subfamily A member 2, Cytochrome P450 1A2, CYPIA2
Function. Metabolism of xenobiotics and drugs. CYP1A1 is involved in phase I xenobiotic and drug metabolism (one substrate of it is theophylline ). It is inhibited by hesperetin (a flavonoid found in lime, sweet orange), [8] fluoroquinolones and macrolides and induced by aromatic hydrocarbons. [9]
- CYP1A1, AHH, AHRR, CP11, CYP1, P1-450, P450-C, P450DX, CYPIA1, cytochrome P450 family 1 subfamily A member 1
其他人也問了
What does CYP1A2 stand for?
Which gene encodes CYP1A2?
What does CYP1A1 do?
What does CYP2E1 stand for?
The enzyme encoded by this gene localizes to the endoplasmic reticulum ( ER) and metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17beta-estradiol . Despite over 20 years of research on CYP1A1 and CYP1A2, CYP1B1 was not identified and sequenced until 1994.
- CYP1B1, CP1B, CYPIB1, GLC3A, P4501B1, cytochrome P450 family 1 subfamily B member 1, ASGD6
Ciprofloxacin inhibits the drug-metabolizing enzyme CYP1A2 and thereby can reduce the clearance of drugs metabolized by that enzyme. CYP1A2 substrates that exhibit increased serum levels in ciprofloxacin-treated patients include tizanidine , theophylline , caffeine , methylxanthines , clozapine , olanzapine , and ropinirole .
Genetic regulation. Chemical regulation. Disease relevance. Applications. See also. References. Further reading. External links. CYP2E1. Cytochrome P450 2E1 (abbreviated CYP2E1, EC 1.14.13.n7) is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body.
Three step CYP1A2 Mediated Metabolism of the prodrug Nabumetone to its active metabolite 6-MNA. [2] Nabumetone, sold under the brand name Relafen among others, is a nonsteroidal anti-inflammatory drug (NSAID). [3] . Nabumetone was developed by Beecham and first received regulatory approval in 1991. [4]
